MedPath

Mechanism of action of 0.1% Tacrolimus ointment in combination with phototherapy in treatment of vitiligo

Not Applicable
Conditions
vitiligo.
Vitiligo
Registration Number
IRCT20181117041686N1
Lead Sponsor
Skin Research Center of Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
30
Inclusion Criteria

patients with symmetrical, unstable and non-segmental vitiligo

Exclusion Criteria

receiving any topical or systemic treatments during the last 3 months
pregnancy, lactation
history of any hypersensitivity to tacrolimus
history of premalignant or malignant skin lesions
photosensitivity, photo-mediated disorders, taking photo-sensitizing drugs
concomitant radiotherapy, chemotherapy, or immunosuppressive therapy
segmental or mucosal vitiligo

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Melanocyte stem cells location. Timepoint: before intervention and 2 months after intervention. Method of measurement: staining of the skin samples using monoclonal antibodies for the melanocytes and assessing the slides under a microscope.
Secondary Outcome Measures
NameTimeMethod
The percentage of skin repigmentation. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Using a quartile grading scale (grade 0, no repigmentation; grade 1, 1%-24%; grade 2, 25%-49%; grade 3, 50%-74%; grade 4, 75%-99%; grade 5, complete resolution).
© Copyright 2025. All Rights Reserved by MedPath